Department of Surgical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, Amsterdam, 1066CX, The Netherlands.
World J Surg Oncol. 2013 Mar 8;11:59. doi: 10.1186/1477-7819-11-59.
Curative surgical treatment of recurrent, locally advanced dermatofibrosarcoma protuberans is often limited owing to a close relation of the tumor with important anatomical structures. Targeted therapy with imatinib, a tyrosine kinase inhibitor, may cause significant reduction of tumor volume, thereby enabling radical surgery. This treatment strategy, therefore, offers a chance of cure for selected patients with advanced dermatofibrosarcoma protuberans. In addition, preoperative treatment with imatinib may decrease possible disfigurement related to radical surgery for large tumors.
由于肿瘤与重要解剖结构关系密切，复发性局部晚期隆突性皮肤纤维肉瘤的治愈性手术治疗往往受到限制。伊马替尼（一种酪氨酸激酶抑制剂）的靶向治疗可能会导致肿瘤体积显著缩小，从而实现根治性手术。因此，对于某些晚期隆突性皮肤纤维肉瘤患者来说，这种治疗策略提供了治愈的机会。此外，伊马替尼的术前治疗可能会减少因大型肿瘤行根治性手术导致的可能畸形。
